[go: up one dir, main page]

MX2008002294A - Derivados de pirimidina sustituida. - Google Patents

Derivados de pirimidina sustituida.

Info

Publication number
MX2008002294A
MX2008002294A MX2008002294A MX2008002294A MX2008002294A MX 2008002294 A MX2008002294 A MX 2008002294A MX 2008002294 A MX2008002294 A MX 2008002294A MX 2008002294 A MX2008002294 A MX 2008002294A MX 2008002294 A MX2008002294 A MX 2008002294A
Authority
MX
Mexico
Prior art keywords
pyrimidine derivatives
potassium channels
kcnq potassium
openers
channels openers
Prior art date
Application number
MX2008002294A
Other languages
English (en)
Inventor
Mario Rottlander
Nikolay Khanzhin
Daniel Rodriguez Greve
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MX2008002294A publication Critical patent/MX2008002294A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a derivados de pirimidina de la formula general I o sus sales. (ver formula I) y su uso.
MX2008002294A 2005-09-09 2006-09-07 Derivados de pirimidina sustituida. MX2008002294A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200501262 2005-09-09
PCT/DK2006/050039 WO2007065449A1 (en) 2005-09-09 2006-09-07 Pyrimidine derivatives and their use as kcnq potassium channels openers

Publications (1)

Publication Number Publication Date
MX2008002294A true MX2008002294A (es) 2008-03-14

Family

ID=37199174

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008002294A MX2008002294A (es) 2005-09-09 2006-09-07 Derivados de pirimidina sustituida.

Country Status (15)

Country Link
EP (1) EP1937653A1 (es)
JP (1) JP2009507052A (es)
KR (1) KR20080043314A (es)
CN (1) CN101258133A (es)
AR (1) AR055420A1 (es)
AU (1) AU2006322461A1 (es)
BR (1) BRPI0615631A2 (es)
CA (1) CA2621854A1 (es)
EA (1) EA200800780A1 (es)
IL (1) IL189545A0 (es)
MX (1) MX2008002294A (es)
NO (1) NO20081713L (es)
UA (1) UA93387C2 (es)
WO (1) WO2007065449A1 (es)
ZA (1) ZA200802174B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA97847C2 (ru) * 2007-08-01 2012-03-26 Х. Луннбек А/С Применение соединений, которые открывают калиевые каналы kcnq, для лечения дефицита внимания/гиперактивности (adhd) или агрессии
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
WO2010097379A1 (en) * 2009-02-24 2010-09-02 Neurosearch A/S Substituted pyrimidin derivatives and their medical use
JP5763758B2 (ja) * 2010-07-08 2015-08-12 ファイザー・インク Ｋｖ７カリウムチャネル開口薬としてのピペリジニルピリミジンアミド
WO2012052167A1 (en) * 2010-10-20 2012-04-26 Grünenthal GmbH Substituted 6-amino-nicotinamides as kcnq2/3 modulators
CN103508960B (zh) * 2012-06-29 2017-12-12 江苏先声药业有限公司 苯并杂环衍生物
CN103508943B (zh) * 2012-06-29 2017-06-09 江苏先声药业有限公司 作为钾通道调节剂的化合物
TWI664166B (zh) * 2014-10-24 2019-07-01 日商小野藥品工業股份有限公司 Ｋｃｎｑ２至５通道活化劑
ES3034153T3 (en) * 2019-08-02 2025-08-13 H Lundbeck As Alcohol derivatives as kv7 potassium channel openers for use in epilepsy or seizures

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2438231A1 (en) * 2001-02-20 2002-08-29 Gene G. Kinney 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators
WO2003068769A1 (en) * 2002-02-12 2003-08-21 Pfizer Inc. Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
US20080261918A1 (en) * 2004-12-17 2008-10-23 Graham Andrew Showell Silicon Compounds and Their Use

Also Published As

Publication number Publication date
AU2006322461A1 (en) 2007-06-14
NO20081713L (no) 2008-06-04
CA2621854A1 (en) 2007-06-14
EP1937653A1 (en) 2008-07-02
WO2007065449A1 (en) 2007-06-14
AR055420A1 (es) 2007-08-22
CN101258133A (zh) 2008-09-03
KR20080043314A (ko) 2008-05-16
EA200800780A1 (ru) 2008-06-30
JP2009507052A (ja) 2009-02-19
IL189545A0 (en) 2008-06-05
ZA200802174B (en) 2009-10-28
UA93387C2 (ru) 2011-02-10
BRPI0615631A2 (pt) 2011-05-24

Similar Documents

Publication Publication Date Title
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
WO2007027238A3 (en) Jak kinase inhibitors and their uses
SG164368A1 (en) Treatment of cancer
WO2010090860A3 (en) Methods and compositions for treating bacterial infection
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
EA200970575A1 (ru) Соединения на основе 4-фенил-6-(2,2,2-трифтор-1-фенилэтокси)пиримидина и способы их применения
UA85559C2 (en) Aminobenzophenone compounds
GEP20094785B (en) Pyrrolopyrazoles, potent kinase inhibitors
WO2009077471A3 (de) Azolylmethyloxirane, ihre verwendung sowie sie enthaltende mittel
ZA200802848B (en) Potassium channel inhibitors
MX2009013515A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica.
MX2009007713A (es) Derivados de piridazina, procedimientos para su preparacion y su uso como fungicidas.
WO2007097981A3 (en) Alpha carbolines and uses thereof
TW200624426A (en) BACE inhibitors
NO20081713L (no) Pyrimidinderivater og deres anvendelse som KCNQ-kaliumkanalapnere
IL205696A0 (en) Heterocyclic derivatives, compositions comprising the same and uses thereof
WO2007067559A3 (en) Antibacterial agents
TW200630367A (en) Substituted adenines and the uses thereof
UA84954C2 (ru) Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования
TW200700064A (en) Novel compounds
WO2006072612A3 (en) Triazolophthalazines as pde2- inhibitors
MX2010009276A (es) Pirrolopirimidincarboxamidas.
MX2009009490A (es) Profarmacos novedosos.
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
PL1937669T3 (pl) Nowe pochodne benzopiranu jako „otwieracze" kanału potasowego

Legal Events

Date Code Title Description
FG Grant or registration